Clinical application of intraperitoneal chemotherapy before surgery for ovarian cancer and its evaluation
- First Online:
- Cite this article as:
- Shi, D., Xiao, M., Chen, S. et al. Chin. -Ger. J. Clin. Oncol. (2009) 8: 260. doi:10.1007/s10330-009-0037-3
To investigate the clinical efficacy of intraperitoneal chemotherapy before surgery for ovarian cancer.
60 patients with stages II–IV of ovarian cancer were treated with intraperitoneal chemotherapy of CAP or TP regimen followed by a surgery treatment and another chemotherapy for 6 cycles. And then the efficiency of the therapy was evaluated by analyzing the changes of ascites, the serum CA-125 and CA-19-9 levels and the findings in the operation, and investigating the recurrence of cancer and the survival.
After 1–3 cycles of intraperitoneal chemotherapy, serum levels of CA-125 and CA-19-9 and carcinous ascites significantly reduced in all patients, ascites reduce was over 50% in 98.3% cases; all cases were successfully treated with cytoreduction and it was found during the operation that bulky tumor was reduced and looser so as to be easily isolated and removed; PFS of the patients was prolonged, while the toxicity and side-effects were not so serious as beyond the patient toleration.
Intraperitoneal chemotherapy before surgery for ovarian cancer has an active efficacy in clinic, being able to improve conditions of surgery and increase the opportunity of maximal cytoreduction, and prolong survival of the patients, and should be a good selection for the treatment of advanced ovarian cancer.